{"address1": "Lichtstrasse 35", "city": "Basel", "zip": "4056", "country": "Switzerland", "phone": "41 61 324 11 11", "fax": "41 61 324 80 01", "website": "https://www.novartis.com", "industry": "Drug Manufacturers - General", "industryKey": "drug-manufacturers-general", "industryDisp": "Drug Manufacturers - General", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Novartis AG engages in the research, development, manufacture, distribution, marketing, and sale of pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor for the treatment of symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still's disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.", "fullTimeEmployees": 75883, "companyOfficers": [{"maxAge": 1, "name": "Dr. Vasant  Narasimhan M.D.", "age": 48, "title": "Chief Executive Officer", "yearBorn": 1976, "fiscalYear": 2024, "totalPay": 7577023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Harry  Kirsch", "age": 59, "title": "Chief Financial Officer", "yearBorn": 1965, "fiscalYear": 2024, "totalPay": 3752236, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Victor  Bulto", "age": 46, "title": "President of US", "yearBorn": 1978, "fiscalYear": 2024, "totalPay": 4033792, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Patrick  Horber M.D.", "age": 54, "title": "President of International", "yearBorn": 1970, "fiscalYear": 2024, "totalPay": 3838140, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Steffen  Lang Ph.D.", "age": 57, "title": "President of Operations", "yearBorn": 1967, "fiscalYear": 2024, "totalPay": 2417433, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Paul  Penepent", "title": "Head of Group Financial Reporting and Accounting", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Sloan  Simpson", "title": "Global Head of Investor Relations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Klaus  Moosmayer Ph.D.", "age": 56, "title": "Chief Ethics, Risk & Compliance Officer", "yearBorn": 1968, "fiscalYear": 2024, "totalPay": 1607206, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Karen L. Hale", "age": 56, "title": "Chief Legal Officer", "yearBorn": 1968, "fiscalYear": 2024, "totalPay": 2424207, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Robert  Kowalski Pharm.D.", "age": 56, "title": "Chief People & Organization Officer", "yearBorn": 1968, "fiscalYear": 2024, "totalPay": 2173620, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "irWebsite": "http://www.novartis.com/investors/index.shtml", "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 109.61, "open": 110.01, "dayLow": 109.35, "dayHigh": 110.83, "regularMarketPreviousClose": 109.61, "regularMarketOpen": 110.01, "regularMarketDayLow": 109.35, "regularMarketDayHigh": 110.83, "dividendRate": 3.87, "dividendYield": 3.53, "exDividendDate": 1741737600, "payoutRatio": 0.6371, "fiveYearAvgDividendYield": 3.64, "beta": 0.49, "trailingPE": 18.838434, "forwardPE": 13.155581, "volume": 2752024, "regularMarketVolume": 2752024, "averageVolume": 2269810, "averageVolume10days": 2717800, "averageDailyVolume10Day": 2717800, "bid": 0.0, "ask": 0.0, "bidSize": 11, "askSize": 9, "marketCap": 222235623424, "fiftyTwoWeekLow": 92.35, "fiftyTwoWeekHigh": 120.92, "priceToSalesTrailing12Months": 4.296733, "fiftyDayAverage": 108.4868, "twoHundredDayAverage": 108.778, "trailingAnnualDividendRate": 3.862, "trailingAnnualDividendYield": 0.03523401, "currency": "USD", "tradeable": false, "enterpriseValue": 234619535360, "profitMargins": 0.23087, "floatShares": 1879297419, "sharesOutstanding": 1975090048, "sharesShort": 4024215, "sharesShortPriorMonth": 3987230, "sharesShortPreviousMonthDate": 1739491200, "dateShortInterest": 1741910400, "sharesPercentSharesOut": 0.002, "heldPercentInsiders": 3.0000001e-05, "heldPercentInstitutions": 0.06718, "shortRatio": 1.92, "shortPercentOfFloat": 0.002, "impliedSharesOutstanding": 2006279936, "bookValue": 22.301, "priceToBook": 4.9670415, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "earningsQuarterlyGrowth": -0.668, "netIncomeToCommon": 11941000192, "trailingEps": 5.88, "forwardEps": 8.42, "lastSplitFactor": "1116:1000", "lastSplitDate": 1554768000, "enterpriseToRevenue": 4.536, "enterpriseToEbitda": 11.355, "52WeekChange": 0.14325523, "SandP52WeekChange": 0.101756096, "lastDividendValue": 3.777, "lastDividendDate": 1709769600, "quoteType": "EQUITY", "currentPrice": 110.77, "targetHighPrice": 125.0, "targetLowPrice": 95.0, "targetMeanPrice": 110.09727, "targetMedianPrice": 110.0, "recommendationMean": 3.25, "recommendationKey": "hold", "numberOfAnalystOpinions": 11, "totalCash": 13351000064, "totalCashPerShare": 6.76, "ebitda": 20661999616, "totalDebt": 31401000960, "quickRatio": 0.792, "currentRatio": 1.035, "totalRevenue": 51721998336, "debtToEquity": 71.162, "revenuePerShare": 25.627, "returnOnAssets": 0.100889996, "returnOnEquity": 0.26275, "grossProfits": 38906998784, "freeCashflow": 12038250496, "operatingCashflow": 17618999296, "earningsGrowth": -0.656, "revenueGrowth": 0.151, "grossMargins": 0.75223, "ebitdaMargins": 0.39948002, "operatingMargins": 0.29938, "financialCurrency": "USD", "symbol": "NVS", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "regularMarketChangePercent": 1.05829, "regularMarketPrice": 110.77, "corporateActions": [], "postMarketTime": 1743636866, "regularMarketTime": 1743624002, "exchange": "NYQ", "messageBoardId": "finmb_382553", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "shortName": "Novartis AG", "longName": "Novartis AG", "epsForward": 8.42, "epsCurrentYear": 8.45615, "priceEpsCurrentYear": 13.099341, "fiftyDayAverageChange": 2.2831955, "fiftyDayAverageChangePercent": 0.021045838, "twoHundredDayAverageChange": 1.9919968, "twoHundredDayAverageChangePercent": 0.018312497, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "3.3 - Hold", "cryptoTradeable": false, "marketState": "PREPRE", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 847377000000, "postMarketChangePercent": -0.595826, "postMarketPrice": 110.11, "postMarketChange": -0.659996, "regularMarketChange": 1.16, "regularMarketDayRange": "109.35 - 110.83", "fullExchangeName": "NYSE", "averageDailyVolume3Month": 2269810, "fiftyTwoWeekLowChange": 18.419998, "fiftyTwoWeekLowChangePercent": 0.19945857, "fiftyTwoWeekRange": "92.35 - 120.92", "fiftyTwoWeekHighChange": -10.150002, "fiftyTwoWeekHighChangePercent": -0.083939806, "fiftyTwoWeekChangePercent": 14.325523, "dividendDate": 1713484800, "earningsTimestamp": 1745908200, "earningsTimestampStart": 1745908200, "earningsTimestampEnd": 1745908200, "earningsCallTimestampStart": 1738328400, "earningsCallTimestampEnd": 1738328400, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": 5.88, "trailingPegRatio": 1.2881}